Shire earnings rise on strong Vyvanse demand

LONDON, April 29 (Reuters) - Strong demand for hyperactivity

treatment Vyvanse helped lift first-quarter earnings 12 percent

at Shire, the London-listed drugmaker that is buying

U.S. rare diseases...

Read more